Mon, Jul 28, 2014, 12:48 AM EDT - U.S. Markets open in 8 hrs 42 mins


% | $
Click the to save as a favorite.

Ironwood Pharmaceuticals, Inc. Message Board

rmsacc 292 posts  |  Last Activity: 11 hours ago Member since: Apr 24, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • rmsacc rmsacc Jul 15, 2014 9:07 AM Flag

    Why do you post here 20 times per day avi ?

  • rmsacc rmsacc Jul 14, 2014 8:56 AM Flag

    Save your breath sabaid, avi is a paid stock basher, paid to discredit the merits of RXI. He will never give reasons for the constant negativity, because he has none............

  • Reply to

    Nuttin but crickets

    by celltones Jul 12, 2014 10:27 PM
    rmsacc rmsacc Jul 13, 2014 8:03 AM Flag

    Brilliant comment, such depth of reasoning. How can we ever thank you?

  • excerpt;

    109 Has the Potential to T
    reat a Wide Range of Indications in Various Therapeutic
    Areas, Representing an
    very significant
    Market Opportunity
    In addition to skin, CTGF plays a
    role in other fibrotic diseases in ophthalmology, lungs, liver, and surgical/abdominal adhesions.
    These ca
    tegories are significant and represent an estimated market opportunity of greater than $10B.
    For example, Lucentis was developed by Roche (SIX: RO) to treat wet macular degeneration and
    diabetic macular edema, which RXI
    109 could potentially treat. In 2010
    , Lucentis brought in sales of
    $2.9B. We believe that there could be several partnering opportunities for RXi to apply the
    Company’s RNAi technology in these therapeutic areas over the next couple of years.
    end excerpt.
    Article proving proof of concept. No doubt on this end that Cauwenbergh is following his quote; "Well conceived plan" Worth a re-read....................GLTA

  • rmsacc rmsacc Jul 12, 2014 7:45 AM Flag

    C'mon avimoron, tell the board the real reasons why you post here so often, c'mon avi tell them.....

  • He served as an Independent Director of Ablynx NV until April 25, 2013. He served as a Member of the Board of Intercept Inc. (US), from 2003 to 2005. He served as a Director of Upstream Biosciences, Inc. from March 25, 2008 to December 14, 2009. He served as a Director of DARA BioSciences, Inc. from June 14, 2008 to April 4, 2009. He served as a Member of the Business Development Council at J&J. Dr. Cauwenbergh served in the R&D organization of the Janssen Research Foundation since 1982, where he served in positions of increasing global responsibility as an International Director of Clinical R&D, Dermatology and Infectious Diseases and oversaw development of drugs such as Sporanox, Nizoral Shampoo, Terazol, and topical Sufrexa. From 2004 to 2006, he served as a Member on the Board of Trustees of the New Jersey Center of Life Sciences. He has authored over 100 publications and co-authored several books. In 2004, he was inducted into the New Jersey High Tech Hall of Fame. Dr. Cauwenbergh received his PhD in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, Belgium where he also completed his Masters and undergraduate work. He holds Bachelor's Degree and Master's Degree from Katholieke Universiteit Leuven.

  • Reply to

    The followin furnished upon request ....

    by rmsacc Jul 11, 2014 2:36 PM
    rmsacc rmsacc Jul 11, 2014 3:12 PM Flag

    It was requested by a hammerjohn9 from a below thread. All you had to do was ask. Looks like you need a little anger management lad..........................

  • Reply to

    The followin furnished upon request ....

    by rmsacc Jul 11, 2014 2:36 PM
    rmsacc rmsacc Jul 11, 2014 3:03 PM Flag

    won't let me post the rest? will put on new thread.....

  • Reply to

    The followin furnished upon request ....

    by rmsacc Jul 11, 2014 2:36 PM
    rmsacc rmsacc Jul 11, 2014 2:53 PM Flag


  • Reply to

    The followin furnished upon request ....

    by rmsacc Jul 11, 2014 2:36 PM
    rmsacc rmsacc Jul 11, 2014 2:43 PM Flag


    where Dr. Cauwenbergh served as Vice President of Technology, where he created technology platforms based on intellectual property and know-how owned by it and developed a business proposition around these platforms as the basis for new companies or new businesses within or outside it. From 1994 to 2000, Dr. Cauwenbergh served as Global Vice President of Research & Development at Johnson & Johnson Consumer Companies Worldwide. He served as Vice President, Research and Development for Johnson & Johnson's Skin Research Center, and was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. Dr. Cauwenbergh served as Vice President, Product Development and a Member of the Management Board of U.S. J&J Consumer Company since 1994. He served as the Director of Corporate Skin Care Council of J&J, co-ordinating all skin care activities in the different operating groups of Corporation. In his career, he served positions in sales, and national and international marketing, and he was responsible for the successful global introduction of Nizoral (ketoconazole). His R&D activities had also involved him in the fields of psoriasis, acne, wound healing, atopic dermatitis, protozoal infections, and HIV. He serves as the Executive Chairman of ECI Biotech. He serves as the Chairman of Expressive Constructs, Inc. He served as the Chairman of BioNJ Inc. He has been a Director of RXi Pharmaceuticals Corporation since May 2012. He has been a Director of Euroscreen S.A since July 2008, Cutanea Life Sciences Inc. since July 9, 2010, Phosphagenics Limited since March 3, 2014 and Moberg Pharma AB (publ) (alternate name: Moberg Derma AB) since April 23, 2012. He serves as a Director of RHEI. He served as an Independent Director of Ablynx NV until April 25, 2013.

  • Geert Cauwenbergh, Ph.D., Med.Sc. has been the Chief Executive Officer and President of RXi Pharmaceuticals Corporation since April 27, 2012, and serves as its Acting Chief Financial Officer. Dr. Cauwenbergh has been the Head of International Advisory Board at Skinvisible Inc. since November 2008. He has been Business Advisor of Edge Therapeutics, Inc., since June 2010. He has been the Official Trade Advisor to the Belgian Government for Health Care in the USA since 2004. He has more than 20 years experience in international research, clinical drug development and new product commercialization for both specialty pharmaceuticals and anti-infectives at both pharmaceutical and biotechnology companies, including Johnson & Johnson (J&J) and the Janssen Research Foundation in Belgium. Dr. Cauwenbergh served as the Chief Executive Officer of RHEI Pharmaceuticals Inc., from August 1, 2008 to June 2011 and also served as its Chairman. He served as Managing Director of the Center for Medical Innovation, a government subsidized center for translational medicine for the Belgian Region of Flanders. Prior to joining RHEI Pharmaceuticals in February 2008, he was a founder and Chief Executive Officer of Phases123, LLC. He founded Barrier Therapeutics Inc. in September 2001 and served as its Executive Chairman from September 2001 to June 2006, Chief Executive Officer from September 2001 to March 31, 2008 and also served as its President. He founded Aramis LLC in May 2009. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. He served at Johnson & Johnson (in both the U.S. and Europe) Consumer and Personal Care Products Companies from 2000 to 2002,

  • Reply to

    Just Bought 20k at 2.26

    by golongn2014 Jul 10, 2014 9:46 AM
    rmsacc rmsacc Jul 11, 2014 1:07 PM Flag

    Certainly a positive p2 will validate sd-rxRNA, the self delivery technology IMO.

    But as Cauwenbergh has mentioned that the "sd" may lend itself useful to the entire Opko RNAi estate that RXI inherited last year, along with any number of RNAi developers whose compounds may be better served with it's use, then I would guess that it has a future outside of rx-109.

    A good question to put to the company wild. They welcome contact and have always shown me the courtesy of a reply....................

  • Reply to

    Just Bought 20k at 2.26

    by golongn2014 Jul 10, 2014 9:46 AM
    rmsacc rmsacc Jul 11, 2014 7:35 AM Flag

    ps. If you read up on Cauwenbergh's career in the life sciences you will find a long history of his mastery of creating value. I will post upon request.....GLTA

  • Reply to

    Just Bought 20k at 2.26

    by golongn2014 Jul 10, 2014 9:46 AM
    rmsacc rmsacc Jul 11, 2014 7:28 AM Flag

    A good deal of speculation has been removed , IMHO. For a $35m m/cap biotech to be in late stage p2 with a blockbuster potential and the foundation for an entire "platform technology" along with a newly patented self delivery for RNAi which we shall be hearing about licensing deals very soon.

    Add to that, available cash and funding into 2016, and zero debt.

    It is a very strong bet That Dr. C. and his staff will advance this company from a $35m cap to a m/cap in the many hundreds of millions within the next two short years.

    I cannot speak for golong, but it is my guess this would be hi answer in part at least...GLTA

  • This must explain why he posts here 20 times per day. You sure have us all fooled avi.............

  • in part; " you have the other side that drives price down to scare the retail buyer. It is easy when they have time on their side. Right? They know for a fact that no real news can happen for a while so they can manipulate and play games until then. At some point they will see news happening and they might not get in at the low but they will cover. It is not the worst game to play with this type of stock."

    A concerted effort of shrewd manipulation? I'm not a market guru, but sure looks like it to me. Notice how they stepped it up past couple of weeks? A bear raid almost every morning. A result of time running low?

    Just my thought this afternoon. btw good post this am jayfeld...............GLTA

  • rmsacc rmsacc Jul 10, 2014 5:31 PM Flag

    orchid, keep in mind the timeliness of the skin healing trials. Although p2 may be slightly delayed, my guess by a slower enrollment due to the greater numbers, (my guess only), the trials began barely a few month ago.

    upon p2 good news I find it unlikely that p3 would vary much,(my guess again).

    So then theoretically 2 years out from now $25 seems very conservative. That would give RXI a m/cap of roughy $340m, or 8.5X todays m/cap, If not mistaken.

    Assuming the low side of the market potential for anti scarring is $1B, (we have heard estimates anywhere from $3-4B, you tell me what the value of the company may be. With your expertise I will defer to you on that one..........................Hope Alls well......................GLTA

  • Reply to

    hedgehog: "the big shot"

    by avl.morax Jul 10, 2014 2:01 PM
    rmsacc rmsacc Jul 10, 2014 2:31 PM Flag

    A legend in his own mind...........................

  • Reply to


    by winthorp.jefferson Jul 10, 2014 1:15 PM
    rmsacc rmsacc Jul 10, 2014 2:14 PM Flag

    Is that you winthorp ?

  • Reply to

    Lots of bravado here today.

    by helpme_hanna Jul 10, 2014 12:42 PM
    rmsacc rmsacc Jul 10, 2014 1:28 PM Flag

    Don't watch too closely hanna, jumping in and out, out and in. It'll drive you nuts. Go read fashion magazines and eat bonbons...............We'll watch the store............

15.36-0.04(-0.26%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.